SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addit...
- Autores:
-
D'Marco, Luis
Morillo, Valery
Gorriz, José Luis
Suarez, María K.
Nava, Manuel
Ortega, Ángel
Parra, Heliana
Villasmil, Nelson
Rojas-Quintero, Joselyn
Bermúdez, Valmore
- Tipo de recurso:
- Fecha de publicación:
- 2021
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/9525
- Palabra clave:
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Glucagon-like peptide 1 receptor agonists (GLP-1RA)
glycemic control
antihyperglycemic
Management of diabetes
Patients obesity and cardiorenal compromise
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional